Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review

ConclusionThe most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of AS, the Herpes Zoster vaccine (HZ/su) (ShingrixTM) which received a license in 2017 from the FDA and a marketing authorization in EU in 2018 and the RTS,S/AS01 vaccine (MosquirixTM) against malaria which was approved by the EMA in 2015 for further implementation in Sub Saharan countries for routine use.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research